Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia

Bibliography

• HARRISON PJ: The neuropathology of. A critical review of the data and their interpretation. Brain (1999) 122:593–624.
   Google Scholar
• •A useful review of the area.
   Google Scholar
• TZSCHENTKE TM: Pharmacology and pharmacology of the dopamine system. Progr: Neurobiol. (2001) 63:241–320.
   PubMed Web of Science ®Google Scholar
• •Excellent review of the current understanding of the dopamine system.
   Google Scholar
• CARLSSON A: The current status of the dopamine hypothesis of schizophrenia. Neuropsychophannacology (1988) 1:179–186.
   PubMed Web of Science ®Google Scholar
• MELTZER HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychophannacology (1989) 99:S18–S27.
   Google Scholar
• MELTZLER HJ: The role of serotonin in antipsychotic drug action. Neurophannacobgy (1999) 21:106s–115s.
   Google Scholar
• BURNETT PWJ, EASTWOOD SL, HARRISON P: 5-HT1A and 5-HT 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychophannacology (1996) 15:443–455.
   Google Scholar
• GUREVICH EV, JOYCE JN: Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry (1997) 42:529–545.
   PubMed Web of Science ®Google Scholar
• GELDERS YJ: Thimostenic agents, a novel approach in the treatment of schizophrenia. Br. J. Psychiatry (Sapp]. 1) (1989) 155:33-36.
   Google Scholar
• DUNBOLT NC: Glutamate uptake. Frog. Neurobiol (2001) 65:1–105.
   Google Scholar
• BRESSAN RA, PILOWSKY LS: Imaging the glutamatergic system in vivo- relevance to schizophrenia. Ear: J. Nucl. Merl (2000) 27:1723–1731.
   PubMedGoogle Scholar
• SIMPSON MDC, SLATER P, JFW: Comparison of glutamate and 7-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia. Biol. Psychiatry (1998) 44:423–427.
   PubMedGoogle Scholar
• OHNUMA T, AUGOOD SJ, ARM H, MCKENNA PJ, EMSON PC: Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and Sin the prefrontal cortex from normal individuals and patients with schizophrenia. Ma Brain Res (1998) 56:207–217.
   Google Scholar
• SCHNEIDER JS, WADE T, LIDSKY TI: Chronic antipsychotic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum. Neuroreport (1998) 9:133–136.
   PubMedGoogle Scholar
• WICKELGREN I: A new route to treating schizophrenia? Science (1998) 281:126–1265.
   Google Scholar
• SIBLEY DR, MONSMA FJ: Molecular biology of dopamine receptors. Trends Pharmacol Sci. (1992) 13:61–69
   PubMed Web of Science ®Google Scholar
• KHAN ZU, GITIERREZ A, MARTIN R, PENAFIEL A, RIVERA A, DE LA CALLE A. Dopamine D5 receptors of rat and human brain. Neuroscience (2000) 100:689–699.
   Google Scholar
• OKUBO Y, SUHARA T, SUZUKY K et al.: Decreased prefrontal D1 receptor in schizophrenia revealed by PET. Nature (1997) 385:634–636.
   PubMed Web of Science ®Google Scholar
• HIRB NJ: The dopamine D4 receptor: a controversial therapeutic target. Drugs future (2000) 25:587–611.
   Google Scholar
• •The role of D4 receptors in the treatment of schizophrenia
   Google Scholar
• SEEMAN PMD, CORBETT R, VAN TOL HHM: Atypical antipsychotics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology(1997) 16:93–110.
   PubMedGoogle Scholar
• PUGSLEY TA, HSIN SHIH Y, WHETZEL SZ et al: The discovery of PD 89211 and related compounds: selective dopamine D4 receptor antagonists. Frog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26:219–226.
   PubMedGoogle Scholar
• SEEMAN PMD, GUAN HG, VAN TOL HHM: Dopamine D4 receptors elevated in schizophrenia. Nature (1993) 365:441–445.
   PubMedGoogle Scholar
• SEEMAN PMD, VAN TOL HHM: Dopamine receptor pharmacology. Trends Pharmacol Sci (1994) 15:264–270.
   PubMedGoogle Scholar
• LAHTI RA, ROBERTS RC, COCHRANE EV, PRIMUS RJ, GALLAGER DW, CONLEY RR: Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]-NGD-94-1 study. Ma Psychiatry (1998) 3:528–533.
   Google Scholar
• BRISTOW LJ, KRAMER MS, J, PATEL S, PAGAN CI, SEABROCK GR: Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci. (1997) 18:186–188.
   PubMedGoogle Scholar
• •The failure of a D4 selective antagonist in the treatment of psychoses.
   Google Scholar
• KRAMER MS, LAST B, GETSON A, REINES SA: The effects of selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic patients with schizophrenia. Arch. Gen. Psych. (1997) 54:568–572.
   Google Scholar
• BARNES NM, SHARP T: A review of central 5-HT receptors and their function. Neuropharmacology (1999) 38:1083–1152.
   PubMed Web of Science ®Google Scholar
• JONES BJ, BLACKBURN TP: The medical benefit of 5-HT research. Pharmacol Biochem. Behav. (2002) 71:555–568.
   PubMed Web of Science ®Google Scholar
• •An interesting collaborative review on 5-HT receptors.
   Google Scholar
• BURNET PW, EASTWOOD SL, HARRISON PJ: 5-HTIA and 5-HT2A receptors mRNAs and binding sites densities are differentially altered in schizophrenia. Neuropharmacology (1997) 15:442–445.
   Google Scholar
• NEWMAN-TANCREDI A, CHAPUT C, VERRIELE L, MILLAN MJ: Cloazapine is a partial agonist at cloned, human serotonin 5-HTIA receptors. Neuropharmacology (1996) 35:119–121.
   PubMed Web of Science ®Google Scholar
• KAPUR S, REMINGTON G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psych.(1996) 15:466–476.
   Google Scholar
• LUCAS G, DE DEURWAERDERE P, CACCIA S, SPAMPINATO U: The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT 2A and 5-HT2c receptor subtypes and significance of the haloperidol dose used. Neuropharmacology (2000) 39:1053–1063.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, MATZUBARA S, LEE J-C: The ratio of serotonin 2 and dopamine 2 affinities diffrentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. (1989) 25(3):390–392.
   PubMedGoogle Scholar
• ROWLEY M, BRISTOW LJ, HUSTON PH: Current and novel approaches to the drug treatment of schizophrenia. I Med. Chem. (2001) 44:477–501.
   PubMed Web of Science ®Google Scholar
• REAVILLC, KETTLE A, HOLLAND V, RILEY G, BLACKBURN TP: Attenuation of haloperidol-induced catalepsy by a 5-HT2c receptor antagonist. Br. Pharmacol (1999) 126:572–574.
   PubMedGoogle Scholar
• COSTALL B, NAYLOR RJ: 5-HT3 receptor antagonism and schizophrenia. In: 5-Hydroxytryptamine-3 receptor antagonists King FD, Jones BJ, Sanger GJ (Eds), CRC Press, Boca Raton (1994a)183–201.
   Google Scholar
• GREENSHAW AJ, SILVERSTONE PH: The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Drugs (1997) 53:20–39.
   PubMed Web of Science ®Google Scholar
• ZOLDAN J, FRIEDBERG G, LIVNEH M,MELAMED E: Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology (1995) 45:1305–1308.
   PubMed Web of Science ®Google Scholar
• KERWIN L, PATELS, MELDRUM BS: Quantitative autoradiographic analysis of glutamate binding sites in hippocampal formations in normal and schizophrenic brains post mortem. Neuroscience (1990) 39:25–32.
   PubMedGoogle Scholar
• MCLAUGHLIN DP, CHEETAM ME, KERWIN L: Expression of alternatively-spiced glutamate receptors in human hippocampus. Eur. Pharmacol. (Molecular Pharmacology) (1993) 244(1):89–92.
   PubMedGoogle Scholar
• DUNCAN GE, SHEITMAN BB, LIEBERMAN JA: An integrated view of pathophysiological models of schizophrenia. (1999) 29:250–264.
   Google Scholar
• GOFF DC, WINE L: Glutamate in schizophrenia: clinical and research implications. Schizophr. Res. (1997) 27:157–168.
   PubMedGoogle Scholar
• ••An excellent overview on the role ofglutamate and glutamate receptors on schizophrenia.
   Google Scholar
• TSAI G, PINCHEN Y, CHUNG L-C, LANGE N, COYLE JT: D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry (1998) 44:1081–1089.
   PubMed Web of Science ®Google Scholar
• WICKELGREN I: A route to treating? Science (1998) 281:1264–1265.
   Google Scholar
• •A good discussion on the treatment of schizophrenia.
   Google Scholar
• PETRALIA RS, WANG Y-X, AS, WENTHOLD RJ: The metabotropic glutamate receptors mGluR2 and mGluR3 show unique postsynaptic presynaptic and glial cell localizations. Neuroscience (1996) 71:949–976.
   PubMedGoogle Scholar
• HERTEL P, FAGERQUIST MV, SVENSSON TH: Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by a2 adrenoceptor blockade. Science (1999) 286:105–107.
   PubMedGoogle Scholar
• ••A great contribution to the definition ofthe relationship between dopamine and adrenergic receptors.
   Google Scholar
• LINDSTROM LH: Schizophrenia, the dopamine hypothesis and a2-adrenoceptor antagonists. Trends Phannacol Sci. (2000)21:198–199.
   PubMedGoogle Scholar
• •Challenging the dopamine hypothesis: an overview on the role of a2 receptor blockade.
   Google Scholar
• ASHBY CR, WANG RJ: Pharmacological actions of the atypical antipsychotic drug clozapine. Synapse (1996) 24:349–394.
   PubMedGoogle Scholar
• MARCUS MM, NOMIKOS GG, SVENSSON TH: Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT 2A and aradrenoceptor antagonism. Eui: Neuropsychophannacol. (2000) 10:245–53.
   PubMedGoogle Scholar
• FELDER CE BYMASTER FP, WARD J, DELAPP N: Therapeutic opportunities for muscarinic receptors in the central nervous system. Med. Chem. (2000) 43:4333–4353.
   Google Scholar
• BRUNELLO N, MASOTTO C, STEARDO L, MARKESTEIN R, RACAGNI G: New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology (1995) 13:177–213.
   PubMed Web of Science ®Google Scholar
• BOWEN WD: Sigma receptors: recent advances and new clinical potential. Pharmaceutica Acta Helvetiae (2000) 74:211–218.
   PubMedGoogle Scholar
• GARDNER I, ZAHID N, D, UETRECHT JP: A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Ma Pharmacol (1998) 53:991–998.
   PubMed Web of Science ®Google Scholar
• GARDNER I, LEEDER JS, CHIN T, N, UETRECHT JP: A comparison of the covalent binding of clozapine and olanzapine to human neutrophils M vitro and in vivo. Mol Pharmacol (1998) 53:999–1008.
   PubMed Web of Science ®Google Scholar
• KOLLER EA, DORAISWAMY PM: Olanzapine-associated diabetes mellitus. Pharmacotherapy (2002) 22:841–852.
   PubMed Web of Science ®Google Scholar
• GEDDES J, FREEMANTLE N, HARRISON P, BEBBINGTON P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. (2000) 321:1371–1376.
   PubMed Web of Science ®Google Scholar
• MCGAWIN JK, GOA KL: Aripiprazole. CNS Drugs (2002) 16:779–786.
   PubMedGoogle Scholar
• MATSUMOTO RR, POUW B: Correlation between antipsychotic binding to 61 and 02 receptors and acute dystonic reactions. Eui: Pharmacol (2000) 401:155–160.
   PubMedGoogle Scholar
• NAKAZATO A, OKUYAMA S: Recent advances in novel atipica antipsychotic agents: potential therapeutic agents for the treatment of schizophrenia. Exp. Opin. Ther. Patents (2000) 10(1):75–98.
   Web of Science ®Google Scholar